Biora Therapeutics Inc Cash Flow Conversion Efficiency
Biora Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Biora Therapeutics Inc (BIOR) has a cash flow conversion efficiency ratio of 0.082x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.73 Million) by net assets ($-106.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biora Therapeutics Inc (2018–2023)
Cash flow conversion efficiency of Biora Therapeutics Inc from 2018 to 2023. This chart illustrates how Biora Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Biora Therapeutics Inc for real-time trading data and today's change.
Biora Therapeutics Inc Cash Flow Conversion Ratio Explained
Biora Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biora Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biora Therapeutics Inc ranked by their cash flow conversion efficiency. Also see BIOR company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KEFI Gold and Copper Plc
LSE:KEFI
|
-0.116x |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
0.028x |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
|
Ridgestone Mining Inc
V:RMI
|
0.012x |
|
Biora Therapeutics, Inc.
NASDAQ:BIORQ
|
0.082x |
|
Foresight Ventures VCT plc
LSE:FVEN
|
N/A |
|
Wingara AG Ltd
AU:WNR
|
-1.348x |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
0.049x |
Annual Cash Flow Conversion Efficiency for Biora Therapeutics Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of Biora Therapeutics Inc from 2018 to 2023. Review BIOR financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-101.42 Million | $-48.50 Million | 0.478x | -24.07% |
| 2022-12-31 | $-102.29 Million | $-64.42 Million | 0.630x | -68.05% |
| 2021-12-31 | $-84.98 Million | $-167.49 Million | 1.971x | +27.23% |
| 2020-12-31 | $-106.99 Million | $-165.74 Million | 1.549x | +22.43% |
| 2019-12-31 | $-83.87 Million | $-106.12 Million | 1.265x | -28.18% |
| 2018-12-31 | $-36.97 Million | $-65.13 Million | 1.762x | -- |
About Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more